Introduction
============

Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a form of non-Hodgkin\'s lymphoma with a low incidence and a geographical predilection to Asia and Latin America [@B1]. ENKTL commonly involves the nasal and paranasal area as well as the upper respiratory and digestive tracts. Approximately two-thirds of cases are stage IE-IIE [@B2], [@B3]. The disease has a poor prognosis and an aggressive clinical course; the 5-year OS rate of patients with early-stage ENKTL is reportedly 38-73% [@B4]-[@B6].

For patients with early-stage ENKTL, radiotherapy alone leads to CR rates of 50-100% [@B4], [@B7]-[@B9], but also carries a high risk of systemic failure in 25-40% of patients with limited-stage disease [@B7]. This suggests that radiotherapy should be combined with chemotherapy to reduce the incidence of distant recurrence.

ENKTL is insensitive to traditional anthracycline-based regimens, as more than 60% of patients become resistant to such therapies [@B10]-[@B13]. The high expression of multi-drug resistance (MDR) genes in ENKTL may lead to poor responses to the conventional CHOP regimen [@B14]. The addition of L-asparaginase/pegaspargase, which is not influenced by MDR genes, has improved the survival rates of patients with ENKTL [@B15], [@B16]. L-asparaginase-based regimens have emerged as potential standard treatments for this condition [@B17]; some of these regimens have achieved CR rates of 40-60% [@B18]-[@B20].

Current effective therapeutic strategies for stage IE-IIE ENKTL include concurrent chemoradiotherapy (CCRT) followed by chemotherapy, sequential chemoradiotherapy, and sandwich chemoradiotherapy [@B21]. Several phase II single-arm clinical trials have demonstrated the promising effects of these treatment modalities. The CR rates following CCRT, sequential chemoradiotherapy, and sandwich chemoradiotherapy are 80-87%, 91-100%, and 74-81%, respectively; the corresponding 5-year OS rates are 72-86%, 86-89%, and 64-85%, respectively [@B22]-[@B30].

Although chemotherapy and radiotherapy are essential for treating early-stage ENKTL, no prospective studies to compare the efficacy of L-asparaginase-based sequential chemoradiotherapy with sandwich chemoradiotherapy have been performed, and the optimal sequence of chemotherapy and radiotherapy has yet to be determined. Therefore, we conducted this multicenter retrospective analysis to compare the objective response rates and survival outcomes between these 2 treatment modalities in patients with ENKTL.

Materials and Methods
=====================

Patients
--------

We retrospectively reviewed the clinical data of 215 treatment-naïve patients with stage IE-IIE ENKTL who attended the Hunan Cancer Hospital, Xiangya Hospital of Central South University or Second Xiangya Hospital of Central South University between 2010 and 2017. ENKTL was diagnosed according to the current World Health Organization classification [@B31], [@B32]. All patients underwent routine blood examinations; blood biochemistry; bone marrow smear and biopsy; CT or MRI of the involved areas; a CT scan of the neck, chest, abdomen, and pelvis; and/or whole-body PET/CT prior to treatment.

Patient characteristics including age, gender, ECOG performance status, Ann Arbor stage, lactate dehydrogenase (LDH) levels, plasma EBV DNA level, B symptoms, PINK and PINK-E scores, local invasion, chemotherapy regimens, and radiotherapy data were collected. Local tumor invasion was defined as occurring when tumors spanned neighboring structures (such as the nasal skin, paranasal sinus, orbit, and hard or soft palate) by contiguous spreading. Stage and risk stratification were determined according to the Ann Arbor stage [@B33], [@B34] and PINK/PINK-E scores [@B35], respectively. Early-stage, limited-stage, and localized ENKTL referred to Ann Arbor stages IE or IIE.

The inclusion criteria were as follows: (1) pathological diagnosis of ENKTL, (2) newly diagnosed patients, (3) Ann Arbor stage IE-IIE, (4) underwent ≥1 cycle of L-asparaginase-based chemotherapy, and (5) underwent radiotherapy. Patients were excluded if they had coexisting malignant tumors, severe organ dysfunction, or any concomitant medical condition that may have caused poor compliance with the research protocol.

All participants provided informed written consent. The study protocol was approved by the Institutional Review Board of the National Cancer Institute and the Ethics Committee of each of the above hospitals. This research was conducted in accordance with the 2008 Declaration of Helsinki.

Treatment and response criteria
-------------------------------

All patients were treated with combined L-asparaginase/pegaspargase-based chemotherapy and radiotherapy. The treatment modalities were categorized into 2 groups based on the timing of radiotherapy in relation to the chemotherapy: the sequential group (induction chemotherapy followed by radiotherapy, or radiotherapy followed by consolidation chemotherapy) and the sandwich group (induction chemotherapy followed by radiotherapy, and then by consolidation chemotherapy). The chemotherapy regimens consisted of GELOX, SMILE, and VLP; the regimens and dosages are listed in Table [1](#T1){ref-type="table"}. The response criteria were evaluated according to the Lugano Response Criteria for non-Hodgkin\'s lymphoma [@B34]. Tumor responses were assessed through physical examinations, nasopharyngoscopy, CT, MRI, and/or PET/CT every 2 cycles during chemotherapy and 1 month after radiotherapy.

Treatment-related toxicity was evaluated according to the National Cancer Institute\'s Common Toxicity Criteria (version 3) [@B36].

Statistical analyses
--------------------

OS was calculated from the date of diagnosis to that of death or the last follow-up date. PFS was defined as the interval between the date of diagnosis and the date of disease progression, relapse, or death by any cause. Differences in patient clinical characteristics, response rates, recurrence rates, and mortality rates between the sequential and sandwich groups were evaluated using the Chi-square or Kruskal-Wallis test. Survival analysis was performed using the Kaplan-Meier method with the log-rank test. Prognostic factors for OS and PFS were analyzed using Cox regression analysis. All statistical analyses were used SPSS 24.0 software (IBM Corp., Armonk, NY, USA). A *p*-value \<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

Between 2010 and 2017, a total of 215 patients with stage IE-IIE ENKTL were enrolled in this retrospective study. These patients were predominantly male (the male: female ratio was 2.6:1). The median patient age was 44 (range, 14-77) years. In terms of treatment, 111 patients were in the sequential group and 104 in the sandwich group. Seventy-eight patients in the sequential group received chemotherapy followed by radiotherapy (CT+RT) while 33 received radiotherapy followed by chemotherapy (RT+CT).

The baseline clinical characteristics, including age (*p* = 0.068), gender (*p* = 0.869), ECOG performance status (*p* = 0.523), LDH levels (*p* = 0.735), B symptoms (*p* = 0.805), PINK scores (*p* = 0.190), PINK-E scores (*p* = 0.449), and local invasion (*p* = 0.317), were largely comparable between the 2 groups. However, significantly more patients with Ann Arbor stage IIE disease were included in the sandwich group (32.7%) than in the sequential group (19.8%; *p* = 0.032) (Table [2](#T2){ref-type="table"}).

Primary tumor sites included the nasal cavities (*N* = 159; sequential group *N* = 79 and sandwich group *N* = 80), upper aerodigestive tract (*N* = 52; sequential group *N* = 29 and sandwich group *N* = 23), and non-upper aerodigestive tract (*N* = 4; sequential group *N* = 3 and sandwich group *N* = 1). Plasma EBV-DNA levels were tested in 94 patients and were detectable in 45 (22 in the sequential group and 23 in the sandwich group).

Adverse events
--------------

The majority of patients tolerated any treatment-related adverse events that occurred, and there were no treatment-related deaths. Neutropenia and radiation-induced mucositis were the most common hematological and non-hematological adverse events, respectively. The incidences of grade 1/2 hematological toxicities and grade 1/2 and 3/4 non-hematological toxicities did not differ significantly between the 2 groups. However, the incidence of grade 3/4 hematological toxicities was significantly higher in the sandwich group than in the sequential group (27.9% *vs*. 15.3%, *p* = 0.025) (Table [3](#T3){ref-type="table"}).

Treatment responses
-------------------

The median radiotherapy dose for both the sequential and sandwich groups was 55.0 Gy (ranges, 40.0-63.0 and 50.0-63.0 Gy, respectively). All patients received a median of 4 (range, 1-8) cycles of chemotherapy. In the sequential group, 84 patients (75.7%) were treated with the GELOX regimen (1-7 cycles), 11 (9.9%) with the SMILE regimen (2-8 cycles), and 16 (14.4%) with the VLP regimen (1-6 cycles). In the sandwich group, 82 patients (78.8%) were treated with the GELOX regimen (2-6 cycles), 11 (10.6%) with the SMILE regimen (3-7 cycles), and 11 (10.6%) with the VLP regimen (2-6 cycles). The proportions of patients receiving each regimen were balanced between the 2 groups.

Across the entire cohort, CR, PR, and PD were observed in 188 (87.4%), 14 (6.5%), and 13 (6.1%) patients, respectively, after the completion of treatment. After the initial chemotherapy, CR, PR, SD, and PD were observed in 53 (47.7%), 56 (50.5%), 1 (0.9%), and 1 (0.9%) patient(s), respectively, in the sequential group. Following sequential chemoradiotherapy, CR, PR, and PD were observed in 95 (85.6%), 7 (6.3%), and 9 (8.1%) patients, respectively. Forty-three patients showed a change from PR to CR, 1 from SD to CR, and 1 from PD to CR. Moreover, 3 patients showed a change from CR to PD and 6 from PR to PD. The remaining 57 patients maintained the initial response. In the sandwich group, CR and PR were observed in 39 (37.5%) and 65 (62.5%) patients, respectively, after the initial chemotherapy. Following sandwich chemoradiotherapy, CR, PR, and PD were observed in 93 (89.5%), 7 (6.7%), and 4 (3.8%) patients, respectively. Thirty-eight patients showed a change from PR to CR and 1 from PR to SD. The remaining 65 patients maintained the initial response. CR rates did not differ significantly between the 2 groups (85.6% *vs.* 89.4% for the sequential and sandwich groups, respectively; *p* = 0.396).

Treatment failure
-----------------

Thirty-seven patients (sequential group *N* = 17 and sandwich group *N* = 20) experienced recurrence during the follow-up period. Nineteen patients developed regional recurrence (sequential group *N* = 8 and sandwich group *N* = 11) and 18 developed distant recurrence (sequential group *N* = 9 and sandwich group *N* = 9). There was no significant difference in recurrence rates between the sequential and sandwich groups (15.3% vs. 19.2%, respectively, p = 0.447).

Survival and prognosis
----------------------

The median follow-up time for all patients was 35.1 (range, 2.6-88.6) months as of October 2017. The median follow-up time for the sequential and sandwich groups were 33.1 (range, 2.6-78.9) and 38.4 (range, 3.6-88.6) months, respectively. The mortality rates were 22.5% (*N* = 25 patients) and 23.1% (*N* = 24 patients), respectively, and were comparable between the 2 treatment modalities (*p* = 0.923).

The 3-year OS and PFS rates for all patients combined were 79.1% and 75.8%, respectively (Figure [1](#F1){ref-type="fig"} A-B). The 3-year OS rates for the sequential and sandwich groups were 77.5% and 80.8%, respectively; the 3-year PFS rates were 74.8% and 76.9%, respectively (Figure [2](#F2){ref-type="fig"}A-B). No significant differences in the 3-year OS or PFS rates were observed between the 2 groups (*p* = 0.636 and *p* = 0.806, respectively).

On univariate analysis, local invasion adversely affected OS, while Ann Arbor stage IE was associated with a favorable OS (Figures [3](#F3){ref-type="fig"}A and [4](#F4){ref-type="fig"}A). On multivariate analysis, local invasion (HR: 0.246, 95% CI: 0.122-0.494; *p* \< 0.001) was the most significant predictor of shorter OS (Table [4](#T4){ref-type="table"}).

Furthermore, univariate analysis revealed that local invasion was associated with poorer PFS, while Ann Arbor stage IE was associated with a favorable PFS (Figures [3](#F3){ref-type="fig"}B and [4](#F4){ref-type="fig"}B). On multivariate analysis, local invasion (HR: 0.317, 95% CI: 0.172-0.583; *p* \< 0.001) and Ann Arbor stage IIE (HR: 1.732, 95% CI: 1.004-2.987; *p* = 0.048) were the most significant predictors of shorter PFS (Table [4](#T4){ref-type="table"}).

Subgroup analysis
-----------------

Among the clinical characteristics examined, only Ann Arbor stage was not balanced between the 2 groups, which is important because Ann Arbor stage notably affected the patients\' prognoses. Therefore, we subsequently performed a subgroup analysis of the Ann Arbor stage. Regardless of stage IE or IIE, clinical characteristics between the sequential and sandwich groups were balanced (Table [S1](#SM0){ref-type="supplementary-material"} and S2). In stage IE patients, the rates of CR, recurrence, 3-year OS, and 3-year PFS in the sequential and sandwich groups were 88.8% vs. 91.4% (p = 0.579), 13.5% vs. 17.1% (p = 0.522), 80.9% vs. 85.7% (p = 0.637), and 79.8% vs. 81.4% (p = 0.991), respectively. In stage IIE patients, these rates were 72.7% vs. 85.3% (p = 0.248), 22.7% vs. 23.5% (p = 0.945), 63.6% vs. 70.6% (p = 0.497), and 54.5% vs. 67.6% (p = 0.356), respectively. Overall, there were no significant differences in objective responses rates and survival outcomes between the 2 groups regardless of stage IE or IIE disease.

Additional analysis was performed to compare the efficacy of RT+CT to that of CT+RT. The clinical features of these 2 groups were balanced (Table [S3](#SM0){ref-type="supplementary-material"}). In the RT+CT group, the initial radiotherapy achieved a CR rate of 66.7% (*N* = 22 patients); in contrast, the CR rate after the initial chemotherapy in the CT+RT group was only 35.9% (*N* = 28). However, the CR rates after completion of chemoradiotherapy were not significantly different between the 2 groups (90.9%*vs.* 83.3% for the RT+CT and CT+RT groups, respectively; *p* = 0.299). The rates of recurrence, 3-year OS, and 3-year PFS also did not differ between the RT+CT and CT+RT groups: 15.2% *vs.* 15.4% (*p* = 0.975), 81.8% *vs.* 75.6% (*p* = 0.291), and 78.8% *vs.* 73.1% (*p* = 0.374), respectively. Taken together, the therapeutic responses and survival outcomes were comparable between the 2 groups.

Discussion
==========

Our study revealed local invasion to be the most significant predictor of poor OS, while both local invasion and Ann Arbor stage IIE are the most significant predictors of poor PFS. For all patients combined, the CR rate as well as the 3-year OS and PFS rates did not significantly differ between the sequential and sandwich groups. Moreover, the response rates and survival outcomes were not significantly different for patients with stage IE and IIE disease between the chemoradiotherapy modalities. Our findings suggest that, as long as radiotherapy and chemotherapy are used in combination, the sequence of treatment may not influence the therapeutic efficacy and survival outcomes in patients with localized ENKTL.

Currently, there are no standard treatment strategies for early-stage ENKTL. CHOP and CHOP-like regimens have proved to be ineffective for ENKTL patients with high recurrence rates and short survival times [@B10], [@B11], [@B13]. Furthermore, several studies [@B37]-[@B39] have demonstrated that L-asparaginase/pegaspargase-based regimens are superior to traditional CHOP or CHOP-like regimens in terms of response rates and survival outcomes. The recommended treatment for limited-stage ENKTL is radiotherapy combined with L-asparaginase/pegaspargase-based chemotherapy. A prospective open-label controlled trial recruited 427 ENKTL patients, of whom 202 received chemoradiotherapy (using cyclophosphamide + methotrexate + etoposide + dexamethasone), 109 received radiotherapy alone, and 116 received the aforementioned chemotherapy regimen alone. Chemoradiotherapy significantly enhanced the CR rate compared to radiotherapy or chemotherapy alone (91% *vs.* 69% *vs.* 59%, respectively; *p \<* 0.01), as it did the 5-year OS rate (86% *vs.* 64% *vs.* 45%, respectively; *p* \< 0.001) [@B27]. A retrospective cohort study of 33 patients treated with chemoradiotherapy (using L-asparaginase + dexamethasone + cisplatin + etoposide + ifosfamide) and 45 patients treated with radiotherapy alone found that the CR rate was higher using chemoradiotherapy than radiotherapy alone (90.9% vs. 77.8%, respectively; p = 0.124), as was the 5-year OS rate (82% vs. 49%, respectively; p \< 0.001) [@B26]. In our current study, we specifically investigated the sequence and appropriate timing of the radiotherapy and chemotherapy combinations.

Kwong *et al.* [@B40] conducted an international multicenter retrospective cohort study comparing sequential chemoradiotherapy to CCRT in patients with early-stage ENKTL. In their study, 54 patients received sequential chemoradiotherapy (chemotherapy + radiotherapy) and 190 received CCRT (CCRT ± chemotherapy); none received anthracycline-containing regimens. No significant differences in the CR, PFS, and OS rates were observed between the sequential chemoradiotherapy and CCRT groups. Additionally, Moon *et al.* [@B41] enrolled 158 stage IE-IIE patients treated with non-anthracycline-based regimens, of whom 61 received sequential chemoradiotherapy (chemotherapy + radiotherapy) and 55 received CCRT (CCRT + chemotherapy). The CR and 5-year OS rates did not differ between the sequential chemoradiotherapy and CCRT groups (82.0% *vs.* 74.5%, respectively, *p* = 0.334; and 77.7 ± 5.5% *vs.* 68.9 ± 6.8%, respectively, *p* = 0.234). These findings indicate that both sequential chemoradiotherapy and CCRT are effective in treating early-stage ENKTL and produce similar outcomes. Consistent with these studies, our own investigation showed that scheduling chemotherapy and radiotherapy in sequential vs. sandwich routines did not affect the survival outcomes of patients with localized ENKTL. In contrast, another retrospective cohort study conducted by Cao *et al.* [@B42] showed that CCRT was associated with a better survival outcome than sequential chemoradiotherapy in limited-stage patients. These conflicting results may be attributable to the fact that patients received less effective CHOP or CHOP-like regimens in Cao *et al.\'s* study. CCRT increases tumor sensitivity to the CHOP regimen, rendering it more effective than sequential chemoradiotherapy. The regimens used in our study have been shown to be more effective than CHOP or CHOP-like regimens for treating ENKTL. Consequently, the radiotherapy scheduling sequence (before, after, or in between chemotherapy) did not significantly impact the outcome.

Treatment-related adverse events were generally consistent in patients undergoing the sequential and sandwich groups, with the exception that grade 3/4 hematological toxicities were slightly more common in the sandwich group. Both sequential and sandwich chemoradiotherapy regimens were tolerated for the treatment of early-stage ENKTL.

Several studies [@B43]-[@B45] have identified local invasion as the most significant factor related to poor survival. Kim *et al.* [@B43] reported that the presence of local tumor invasion predicted an inferior CR rate and poor survival outcomes in patients with stage IE-IIE ENKTL of the upper aerodigestive tract. Consistent with these findings, our study found that local invasion (i.e., tumors invading adjacent bone, skin, and soft tissues) was the most significant predictor of poorer OS and PFS rates. The PINK and PINK-E scoring systems were proposed by Kim *et al.* [@B35] in 2016 as a prognostic index for ENKTL patients receiving non-anthracycline-containing regimens. The PINK model comprises 4 independent risk factors: \>60 years of age, advanced-stage disease, distant lymph node invasion, and non-nasal type disease. The PINK-E (comprising the 4 independent risk factors of PINK combined with pretreatment plasma EBV-DNA copy number) also predicts survival. In their study, the 3-year OS rates in the low-, intermediate-, and high-risk groups were 81%, 62%, and 25% using the PINK model, and 81%, 55%, and 28% using the PINK-E model, respectively. Our results showed that the 3-year OS rates of both the low- and intermediate-risk groups were consistent with those of Kim *et al.* [@B35]; however, PINK and PINK-E had no predictive significance for survival outcomes on multivariate analysis. This may be due to the limited number of elderly patients (aged \>60 years) (*N* = 18; 8.4%), a lack of distant lymph node invasion (*N* = 2; 0.9%), and the fact that baseline EBV-DNA data were unavailable for \>50% of the patients (*N* = 121).

Our study was a multi-center investigation; however, there were certain limitations in this study. It was a retrospective analysis comprising a relatively small sample size; moreover, patients received non-uniform chemotherapy regimens and were administered varying radiotherapy dosages.

In conclusion, our results showed that, in the era of L-asparaginase/pegaspargase, the timing and sequence of chemotherapy and radiotherapy may not affect the therapeutic responses or survival outcomes in newly diagnosed patients with stage IE-IIE ENKTL as long as both are used in combination. Future large-scale, prospective, multicenter studies are required to validate these findings.
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ENKTL

:   extranodal natural killer/T-cell lymphoma, nasal type

CR

:   complete response

MDR

:   multi-drug resistance

CHOP

:   cyclophosphamide, anthracycline, vincristine, and prednisone

CCRT

:   concurrent chemoradiotherapy

CT

:   computed tomography

MRI

:   magnetic resonance imaging

PET

:   positron emission tomography

ECOG

:   Eastern Cooperative Oncology Group

LDH

:   lactate dehydrogenase

EBV

:   Epstein-Barr virus

PINK

:   prognostic index for natural killer/T-cell lymphoma

GELOX

:   gemcitabine, oxaliplatin, and L-asparaginase/pegaspargase

SMILE

:   dexamethasone, methotrexate, ifosfamide, L-asparaginase/pegaspargase, and etoposide

VLP

:   vincristine, L-asparaginase/pegaspargase, and prednisone

OS

:   overall survival

PFS

:   progression-free survival

PR

:   partial response

CT+RT

:   chemotherapy followed by radiotherapy

RT+CT

:   radiotherapy followed by chemotherapy

PD

:   progressive disease

SD

:   stable disease

HR

:   hazard ratio

CI

:   confidence interval.

![Kaplan-Meier survival curves for all patients. A) Overall survival; the 3-year rate was 79.1%. B) Progression-free survival; the 3-year rate was 75.8%.](jcav09p1598g001){#F1}

![Kaplan-Meier survival curves plotted according to treatment modality. A) Overall survival; the 3-year rates in the sequential and sandwich groups were 77.5% and 80.8%, respectively (*p* = 0.636). B) Progression-free survival; the 3-year rates in the sequential and sandwich groups were 74.8% and 76.9%, respectively (*p* = 0.806).](jcav09p1598g002){#F2}

![Kaplan-Meier survival curves in patients with (present) and without (absent) local invasion. A) Overall survival; the 3-year rates in the present and absent groups were 68.1% and 91.2%, respectively (*p* \< 0.001). B) Progression-free survival; the 3-year rates in the present and absent groups were 64.6% and 88.2, respectively (*p* \< 0.001).](jcav09p1598g003){#F3}

![Kaplan-Meier survival curves in patients with Ann Arbor stage IE and IIE extranodal natural killer/T-cell lymphoma, nasal type. A) Overall survival; the 3-year rates in patients with stage IE and stage IIE disease were 83.0% and 67.9%, respectively (*p* = 0.029). B) Progression-free survival; the 3-year rates in patients with stage IE and stage IIE disease were 80.5% and 62.5%, respectively (*p* = 0.012).](jcav09p1598g004){#F4}

###### 

Chemotherapy regimens

  Regimen   Drugs                         Dosage
  --------- ----------------------------- ------------------------------------
  GELOX     gemcitabine                   800 mg/m^2^, d1 and d8
            oxaliplatin                   85 mg/m^2^, d1
            L-asparaginase/pegaspargase   5000 U/m^2^, d1-7/2500 IU/m^2^, d1
  SMILE     dexamethasone                 15 mg, d1-7
            methotrexate                  60 mg/m^2^, d1
            ifosfamide                    1.5 g/m^2^, d2-4
            L-asparaginase/pegaspargase   5000 U/m^2^, d1-7/2500 IU/m^2^, d1
            etoposide                     100 mg/m^2^, d2-4
  VLP       vincristine                   2 mg, d1
            L-asparaginase/pegaspargase   5000 U/m^2^, d1-7/2500 IU/m^2^, d1
            prednisone                    100 mg/d, d1-5

###### 

Patient characteristics

  Characteristic             Sequential Group   Sandwich Group   *p*   All n (%)
  -------------------------- ------------------ ---------------- ----- ------------
  **Gender**                                    0.869                  
  Male                       80 (72.1)          76 (73.1)              156 (72.6)
  Female                     31 (27.9)          28 (26.9)              59 (27.4)
  **Age**                                       0.068                  
  \>60                       13 (11.7)          5 (4.8)                18 (8.4)
  ≤60                        98 (88.3)          99 (95.2)              197 (91.6)
  **ECOG**                                      0.523                  
  0-1                        110 (99.1)         102 (98.1)             212 (98.6)
  2-4                        1 (0.9)            2 (1.9)                3 (1.4)
  **Ann Arbor stage**                           0.032                  
  IE                         89 (80.2)          70 (67.3)              159 (74.0)
  IIE                        22 (19.8)          34 (32.7)              56 (26.0)
  **LDH**                                       0.735                  
  Elevated                   30 (27.0)          26 (25.0)              56 (26.0)
  Normal                     81 (73.0)          78 (75.0)              159 (74.0)
  **B symptoms**                                0.805                  
  Present                    68 (61.3)          62 (59.6)              130 (60.5)
  Absent                     43 (38.7)          42 (40.4)              85 (39.5)
  **PINK**                                      0.190                  
  Low-risk                   94 (84.7)          96 (92.3)              190 (88.4)
  Intermediate-risk          16 (14.4)          7 (6.7)                23 (10.7)
  High-risk                  1 (0.9)            1 (1.0)                2 (0.9)
  **PINK-E**                                    0.449                  
  Low-risk                   45 (91.8)          42 (93.4)              87 (92.5)
  Intermediate-risk          4 (8.2)            2 (4.4)                6 (6.4)
  High-risk                  0 (0.0)            1 (2.2)                1 (1.1)
  **Local invasion**                            0.317                  
  Present                    62 (55.9)          51 (49.0)              113 (52.6)
  Absent                     49 (44.1)          53 (51.0)              102 (47.4)
  **Chemotherapy regimen**                      0.697                  
  GELOX                      84 (75.7)          82 (78.8)              166 (77.2)
  SMILE                      11 (9.9)           11 (10.6)              22 (10.2)
  VLP                        16 (14.4)          11 (10.6)              27 (12.6)

###### 

Adverse events

                           Grade 1-2          Grade 3-4                                                    
  ------------------------ ------------------ ---------------- ------- ------------------ ---------------- -------
  Adverse events           Sequential group   Sandwich group   *p*     Sequential group   Sandwich group   *p*
  Hematological            73 (65.8%)         68 (65.4%)       0.953   17 (15.3%)         29 (27.9%)       0.025
  Neutropenia              41 (36.9%)         47 (45.2%)       0.219   17 (15.3%)         27 (26.0%)       0.053
  Anemia                   50 (45.0%)         47 (45.2%)       0.983   2 (1.8%)           2 (1.9%)         0.948
  Thrombocytopenia         17 (15.3%)         13 (12.5%)       0.552   6 (5.4%)           5 (4.8%)         0.842
  Non-hematological        60 (54.1%)         57 (54.8%)       0.912   21 (18.9%)         18 (17.3%)       0.759
  Nausea/Vomiting          35 (31.5%)         41 (39.4%)       0.226   6 (5.4%)           8 (7.7%)         0.497
  Transaminase elevation   47 (42.3%)         42 (40.4%)       0.771   4 (3.6%)           2 (1.9%)         0.455
  Radio-mucositis          37 (33.3%)         35 (33.7%)       0.960   12 (10.8%)         12 (11.5%)       0.866
  Radio-dermatitis         16 (14.4%)         22 (21.2%)       0.195   3 (2.7%)           2 (1.9%)         0.705

###### 

Univariate and multivariate analyses for factors affecting survival outcomes

  Clinical factor              Overall survival   Progression-free survival                                                                              
  ---------------------------- ------------------ --------------------------- --------- --------------------- --------- ---------------------- --------- ---------------------
  Female                       0.061              0.485 (0.227-1.035)                                         0.081     0.544 (0.274-1.077)              
  Age ≤ 60                     0.088              0.498 (0.224-1.109)                                         0.055     0.481 (0.227-1.017)              
  ECOG 0-1                     0.476              0.487 (0.067-3.531)                                         0.546     0.544 (0.075-3.934)              
  Ann Arbor stage IIE          0.029              1.892 (1.058-3.385)                                         0.012     1.982 (1.153-3.407)    0.048     1.732 (1.004-2.987)
  Normal LDH                   0.811              0.927 (0.499-1.723)                                         0.777     0.920 (0.515-1.643)              
  Absent B symptoms            0.876              0.955 (0.538-1.697)                                         0.975     0.991 (0.580-1.695)              
  PINK Intermediate-risk       0.165              1.711 (0.802-3.650)                                         0.140     1.713 (0.839-3.498)              
  PINK-E Intermediate-risk     0.249              2.425 (0.537-10.951)                                        0.285     2.265 (0.507-10.122)             
  Absent local invasion        \<0.001            0.233 (0.116-0.467)         \<0.001   0.246 (0.122-0.494)   \<0.001   0.299 (0.163-0.548)    \<0.001   0.317 (0.172-0.583)
  Sandwich chemoradiotherapy   0.636              1.070 (0.808-1.417)                                         0.806     1.033 (0.795-1.343)              
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